Indolent Lymphoma
News
Ibrutinib highly active against refractory Waldenstrom’s macroglobulinemia
Key clinical point: Ibrutinib produced a 90.5% overall response rate and a 73% major response rate in a proof-of-concept trial of 63 patients with...
Case Reports
Diffuse large B-cell lymphoma of the lung in a 63-year-old man with left flank pain
Conference Coverage
No survival benefit for routine surveillance scans in classical Hodgkin disease
Major finding: The ratio of scans to detected relapses was 18 for the clinical surveillance group and 124 for the routine scan group.